Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -45.43M | -49.73M | -44.00M | -42.61M | -27.90M |
| Total Depreciation and Amortization | 1.56M | 1.56M | 1.56M | 1.21M | 1.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.30M | 10.44M | 8.84M | 7.94M | 817.10K |
| Change in Net Operating Assets | 1.20M | -475.60K | -7.74M | 11.46M | -2.18M |
| Cash from Operations | -23.37M | -38.20M | -41.33M | -22.01M | -28.06M |
| Capital Expenditure | -1.20M | -1.20M | -1.20M | -234.50K | -234.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -85.80K | -177.00K | -84.70K | -968.30K | -366.20K |
| Cash from Investing | -1.29M | -1.38M | -1.29M | -1.20M | -600.80K |
| Total Debt Issued | 962.89M | 962.89M | 962.89M | 255.28M | 255.28M |
| Total Debt Repaid | -740.16M | -739.11M | -736.61M | -11.73M | -11.41M |
| Issuance of Common Stock | 14.00K | -- | -- | 31.48M | 31.48M |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.63M | -26.63M | -26.63M | -1.26M | -1.26M |
| Cash from Financing | 18.44M | 18.53M | 18.77M | 25.55M | 25.57M |
| Foreign Exchange rate Adjustments | -492.40K | 1.55M | -2.47M | 1.66M | 3.92M |
| Miscellaneous Cash Flow Adjustments | -100.00 | -200.00 | -100.00 | 100.00 | 100.00 |
| Net Change in Cash | -6.71M | -19.49M | -26.32M | 4.00M | 836.50K |
